Efficacy and Safety of Irinotecan Liposome Injection Combined With 5-FU/LV± Immunotherapy in First-line Gemsitabine + Immunoprogressive Patients With Metastatic Biliary Tract Cancer

Launched by TIANJIN MEDICAL UNIVERSITY CANCER INSTITUTE AND HOSPITAL · Feb 21, 2024

Keywords

ClinConnect Summary

This clinical trial is investigating a new treatment approach for patients with metastatic biliary tract cancer, which is cancer that has spread from the bile ducts. The researchers are looking at a combination of a medication called irinotecan liposome injection with other drugs, including 5-FU and leucovorin, and possibly immunotherapy. This study aims to determine how effective and safe this combination is for patients who have already undergone treatment with gemcitabine and immunotherapy but whose cancer has progressed.

To participate in this trial, patients must be between 18 and 75 years old and have a confirmed diagnosis of cholangiocarcinoma, a type of bile duct cancer, with measurable disease. They should also be in relatively good health, meaning they have no severe organ problems and can carry out daily activities. Participants can expect to receive regular monitoring and care throughout the study, and they will be asked to provide informed consent before starting. This trial offers hope for better treatment options for patients with advanced biliary tract cancer who have exhausted previous therapies.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. The patient had good compliance, could understand the research process of the study, and signed a written informed consent;
• • 2. Age ≥18 years, ≤75 years;
• • 3. Histologically or cytologically confirmed cholangiocarcinoma;
• • 4. Documented metastatic disease;
• • 5. At least one measurable lesion according to RECIST v1.1;
• • 6. Disease progression after gemcitabine + immunotherapy;
• • 7. For patients whose disease recurred after curative resection (R0 or R1), previous adjuvant 5-FU-based chemotherapy is allowed if there is at least 6 month-interval between the last dose of adjuvant chemotherapy and recurrence of disease;
• • 8. Eastern Cooperative Oncology Group (ECOG) Performance status 0-1;
• • 9. The expected survival time is greater than 3 months;
• 10. Having adequate organ function, as defined below:
• • 1. Absolute neutrophil count (ANC) ≥1.5\*109/L
• • 2. Hemoglobin ≥90g/dL
• • 3. Platelets (PLT) ≥100\*109/L
• • 4. Total bilirubin \< 1.5 times Upper Normal Value (ULN)
• • 5. Chemical examination of liver function index (AST\&ALT) \< 2.5 times Upper Limit of Normal (ULN)
• • 6. Serum creatinine (Cr) ≤1.5×ULN
• • 11. Non-pregnant or lactating women; Effective contraception should be used by women/men of childbearing age during the study period and for 6 months after the end of study treatment-
• Exclusion Criteria:
• • （1) Serum total bilirubin ≥2 x ULN (upper limit of normal) (biliary obstruction allows biliary drainage); （2）Severe renal impairment (Clcr ≤ 30 ml/min); （3）Any clinically significant disorder impacting the risk-benefit balance negatively per physician's judgment； （4）Any clinically significant gastrointestinal disorder, including hepatic disorders, bleeding, inflammation, occlusion, or diarrhea \> grade 2; （5）Severe arterial thromboembolic events (myocardial infarction, unstable angina pectoris, stroke) in last 6 months; （6） NYHA(New York Heart Association) Class III or IV congestive heart failure, ventricular arrhythmias or uncontrolled blood pressure. Or known abnormal ECG with clinically significant abnormal findings; （7） Active infection or an unexplained fever \>38.5°C (excluding tumor fever), which in the physician's opinion might compromise the patient's health; （8） Current use or any use in last two weeks of strong CYP3A-enzyme inducers/inhibitors and/or strong UGT1A inhibitors； （9） Known hypersensitivity to any of the components of Onivyde other liposomal irinotecan formulations, irinotecan, fluoropyrimidines, or leucovorin; （10）Breast feeding, known pregnancy, positive serum pregnancy test or unwillingness to use an effective method of contraception, during therapy and for 3 months following the last dose of Onivyde. Females of Childbearing Potential must either agree to use and be able to take effective contraceptive birth control measures (Pearl Index \< 1) or agree to practice complete abstinence from heterosexual intercourse during the course of the study and for at least 3 months after last application of program treatment. A female subject is considered to be of childbearing potential unless she is age ≥ 50 years and naturally amenorrhoeic for ≥ 2 years, or unless she is surgically sterile. Males must agree not to father a child (including not donating sperm) during the course of the trial and for at least 6 months after last administration of study drugs; （11） Previous treatment with combination drug tegafur, gimeracil, and oteracil potassium with seven days before enrollment; （12） Current treatment with Sorivudine; （13） Severe fatigue or bone marrow depression after prior radiotherapy or antineoplastic therapy; （14）There are serious concomitant diseases, such as diabetes mellitus and can not be well controlled by hypoglycemic drugs, clinically serious (that is, active) heart disease, renal failure, liver failure, uncontrolled epilepsy, central nervous system disease or history of mental disorders, hemorrhagic peptic ulcer, intestinal paralysis, intestinal obstruction, etc.; （15） History of other malignancy with a disease-free interval \<5 years (Registration is permitted if it has minimal impact on prognosis, such as carcinoma in situ and papillary thyroid cancer); （16） History or current eveidence of brain metastasis; （17）Patients deemed unsuitable for this trial by the investigator.